Can Fenofibrate and Lovaza Be Combined for Triglyceride Lowering?
Yes, fenofibrate can be safely combined with Lovaza (omega-3-acid ethyl esters) for triglyceride lowering, and this combination is reasonable when clinically indicated, particularly in patients with persistent severe hypertriglyceridemia (≥500 mg/dL) despite monotherapy. 1
Evidence Supporting the Combination
The combination of fenofibrate with omega-3 fatty acids has a favorable safety profile compared to other fibrate combinations. When statin-fibrate combination therapy is indicated, fenofibrate is preferred over gemfibrozil because of a reduced incidence of drug-drug interactions 1. This principle extends to omega-3 combinations as well.
Clinical Trial Data
A randomized controlled trial directly evaluated this combination in patients with severe hypertriglyceridemia (≥500 mg/dL). The study compared fenofibrate 130 mg plus prescription omega-3 fatty acids 4g daily versus fenofibrate monotherapy over 8 weeks 2. Key findings:
- Concomitant therapy reduced median triglycerides from 649.5 to 267.5 mg/dL (60.8% reduction) versus 669.3 to 310 mg/dL (53.8% reduction) with fenofibrate alone (p=0.059) 2
- When omega-3 was added to patients already stable on fenofibrate monotherapy, triglycerides decreased an additional 17.5% (p=0.003) 2
- The combination was well tolerated with no significant safety signals 2
Guideline Support
Multiple guidelines support this approach:
- ACC/AHA guidelines classify omega-3 fatty acids (2-4g daily) as Class IIb for elevated triglyceride treatment 3, 4, 5, 4, 5
- European guidelines state that prescription omega-3 fatty acids might be added if elevated triglycerides are not adequately decreased with fibrates alone 6
- Canadian guidelines specifically note that adding omega-3 fatty acids (2-4g three times daily) to statin therapy is safe and may help achieve lipid targets 7
Clinical Algorithm for Use
When to consider the combination:
- Triglycerides ≥500 mg/dL despite lifestyle modifications and single-agent therapy 8
- Triglycerides 200-499 mg/dL with inadequate response to fenofibrate monotherapy and non-HDL-C not at goal 3, 5
- Patients already on statins with persistent hypertriglyceridemia where additional triglyceride lowering is needed 7
Dosing:
- Fenofibrate: Standard dosing (typically 145-160 mg daily or 130 mg for micronized formulation)
- Lovaza: 4 grams daily (either as single 4-gram dose or two 2-gram doses) 8
Safety Considerations
The combination is generally well tolerated 2, 9. Important monitoring includes:
- Periodic monitoring of ALT/AST (both agents can affect liver function) 8
- LDL-C levels (omega-3 products containing DHA may increase LDL-C, though this is less concerning when non-HDL-C remains controlled) 8, 9, 10
- Bleeding time if patient is on anticoagulants or antiplatelet agents (omega-3 fatty acids may prolong bleeding time) 8
- Atrial fibrillation monitoring, particularly in the first months of therapy, as there is a possible association with more frequent recurrences in susceptible patients 8, 11
Critical Caveat About Body Weight
The modest caloric contribution of Lovaza (approximately 44 Cal/day from 4g daily dosing) does not alter body weight or waist circumference when used for up to 16 weeks, even in overweight/obese patients 12. This addresses a common concern about adding oil-based supplements.
Advantages Over Alternative Combinations
Fenofibrate is strongly preferred over gemfibrozil for any combination therapy. The AHA scientific statement on drug-drug interactions explicitly recommends avoiding gemfibrozil with statins due to severe myopathy risk, while fenofibrate combinations are considered reasonable 1. This safety advantage extends to omega-3 combinations as well.
Fenofibrate plus omega-3 is safer than high-dose statin plus fibrate combinations, which carry increased myopathy risk and require keeping statin doses relatively low 3, 4, 5, 4, 5.
Limitations
The effect of this combination on cardiovascular mortality and morbidity has not been definitively established 8. The primary indication remains triglyceride reduction to prevent pancreatitis in severe hypertriglyceridemia and to address residual cardiovascular risk associated with elevated triglycerides.
Recent large trials of low-dose omega-3 mixtures (EPA+DHA) have not shown cardiovascular benefit in contemporary populations on background statin therapy 13, though these studies used lower doses (1g daily) than the prescription dose for hypertriglyceridemia (4g daily).